This finding suggests that targeting IL-6 or its receptor could be a potential therapeutic strategy for keloids, as it may disrupt the JAK-STAT pathway and its downstream effects on cell proliferation and collagen synthesis. This evidence concerns the gene SOAT1 and keloid.